Cervical cancer remains one of the most common and deadly cancers in women, especially in regions like sub-Saharan Africa. In this study, two therapeutic approaches were explored to improve treatment outcomes: interleukin-2 immunotherapy and a combined strategy with chemotherapy.

The first approach focused on using interleukin-2 (IL-2), a cytokine that enhances the immune system to fight cancer cells. The study found that, under certain conditions, IL-2 could slow the progression of cervical cancer.

Building on this, the second approach evaluated the combination of chemotherapy and immunotherapy. The results demonstrated that combining these therapies is more effective at reducing cancer progression than using them separately.

To optimize the delivery of these treatments, an optimization method was applied, ensuring that the combined therapy is administered efficiently. This approach can be particularly beneficial for regions with limited healthcare resources, providing a promising strategy for managing cervical cancer.

This research suggests that combining chemotherapy with immunotherapy, specifically using IL-2, offers a significant improvement in cervical cancer treatment, particularly in areas where cancer rates are high, such as sub-Saharan Africa.